Compare SRRK & CHRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRRK | CHRD |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 8.0B |
| IPO Year | 2018 | 2010 |
| Metric | SRRK | CHRD |
|---|---|---|
| Price | $41.57 | $151.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 18 |
| Target Price | $70.44 | ★ $176.88 |
| AVG Volume (30 Days) | ★ 1.8M | 584.2K |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 3.37% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 11.14 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $49.78 |
| Revenue Next Year | $2,404.46 | N/A |
| P/E Ratio | ★ N/A | $13.89 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.07 | $84.25 |
| 52 Week High | $61.76 | $157.06 |
| Indicator | SRRK | CHRD |
|---|---|---|
| Relative Strength Index (RSI) | 30.05 | 68.26 |
| Support Level | $39.69 | $130.44 |
| Resistance Level | $48.59 | $157.06 |
| Average True Range (ATR) | 1.89 | 3.60 |
| MACD | -0.23 | 1.92 |
| Stochastic Oscillator | 14.72 | 98.49 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Chord Energy Corp is an independent exploration and production (E&P) company engaged in the acquisition, exploration, development and production of crude oil, NGL and natural gas prominently in the Williston Basin, with limited non-operated interests in the Marcellus Shale. It operates in one reportable business segment, which is the E&P of crude oil, NGL and natural gas. The company derives revenue from the sale of crude oil, NGL and natural gas production.